How will HPV vaccines affect cervical cancer?

被引:211
作者
Roden, Richard [1 ]
Wu, T. -C.
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD 21231 USA
[4] Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD 21231 USA
关键词
D O I
10.1038/nrc1973
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with `high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.
引用
收藏
页码:753 / 763
页数:11
相关论文
共 121 条
[1]   Women's desired information about human papillomavirus [J].
Anhang, R ;
Wright, TC ;
Smock, L ;
Goldie, SJ .
CANCER, 2004, 100 (02) :315-320
[2]   A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine [J].
Ault, KA ;
Giuliano, AR ;
Edwards, RP ;
Tamms, G ;
Kim, LL ;
Smith, JF ;
Jansen, KU ;
Allende, M ;
Taddeo, FJ ;
Skulsky, DM ;
Barr, E .
VACCINE, 2004, 22 (23-24) :3004-3007
[3]   Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses [J].
Barnabas, Ruanne V. ;
Laukkanen, Paivi ;
Koskela, Pentti ;
Kontula, Osmo ;
Lehtinen, Matti ;
Garnett, Geoff P. .
PLOS MEDICINE, 2006, 3 (05) :624-632
[4]   Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1 [J].
Baud, D ;
Ponci, F ;
Bobst, M ;
De Grandi, P ;
Nardelli-Haefliger, D .
JOURNAL OF VIROLOGY, 2004, 78 (23) :12901-12909
[5]   Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium [J].
Baud, D ;
Benyacoub, J ;
Revaz, W ;
Kok, M ;
Ponci, F ;
Bobst, M ;
Curtiss, R ;
De Grandi, P ;
Nardelli-Haefliger, D .
INFECTION AND IMMUNITY, 2004, 72 (02) :750-756
[6]   A FORMALIN-INACTIVATED VACCINE PROTECTS AGAINST MUCOSAL PAPILLOMAVIRUS INFECTION - A CANINE MODEL [J].
BELL, JA ;
SUNDBERG, JP ;
GHIM, SJ ;
NEWSOME, J ;
JENSON, AB ;
SCHLEGEL, R .
PATHOBIOLOGY, 1994, 62 (04) :194-198
[7]   A review of human papillomavirus vaccines: From basic science to clinical trials [J].
Berry, JM ;
Palefsky, JM .
FRONTIERS IN BIOSCIENCE, 2003, 8 :S333-S345
[8]   Solid cancers after bone marrow transplantation [J].
Bhatia, S ;
Louie, AD ;
Bhatia, R ;
O'Donnell, MR ;
Fung, H ;
Kashyap, A ;
Krishnan, A ;
Molina, A ;
Nademanee, A ;
Niland, JC ;
Parker, PA ;
Snyder, DS ;
Spielberger, R ;
Stein, A ;
Forman, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :464-471
[9]   ANTIBODY-MEDIATED NEUTRALIZATION OF HUMAN PAPILLOMAVIRUS TYPE-11 (HPV-11) INFECTION IN THE NUDE-MOUSE - DETECTION OF HPV-11 MESSENGER-RNAS [J].
BONNEZ, W ;
ROSE, RC ;
REICHMAN, RC .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (02) :376-380
[10]   The causal relation between human papillomavirus and cervical cancer [J].
Bosch, FX ;
Lorincz, A ;
Muñoz, N ;
Meijer, CJLM ;
Shah, KV .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265